<?xml version="1.0" encoding="UTF-8"?>
<ref id="B33-vaccines-07-00074">
 <label>33.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Piantadosi</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Panteleeff</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Blish</surname>
    <given-names>C.A.</given-names>
   </name>
   <name>
    <surname>Baeten</surname>
    <given-names>J.M.</given-names>
   </name>
   <name>
    <surname>Jaoko</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>McClelland</surname>
    <given-names>R.S.</given-names>
   </name>
   <name>
    <surname>Overbaugh</surname>
    <given-names>J.</given-names>
   </name>
  </person-group>
  <article-title>Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression</article-title>
  <source>J. Virol.</source>
  <year>2009</year>
  <volume>83</volume>
  <fpage>10269</fpage>
  <lpage>10274</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.01149-09</pub-id>
  <?supplied-pmid 19640996?>
  <pub-id pub-id-type="pmid">19640996</pub-id>
 </element-citation>
</ref>
